| This week's sponsor is CMIC Group. | | | Partner with Japan’s Largest CRO for your global drug development
CMIC is the largest CRO in Japan, with extended services in drug development and GMP manufacturing, site management, regulatory consulting and contract sales. We have the full end to end solution to help you enter Japan market and fulfill your drug development and manufacturing needs in US, Japan and Asia.
To learn more, click here. |
Today's Rundown Celgene strikes Obsidian deal to boost CAR-T options Novartis allies with Oxford academics for big data R&D drive Apple, J&J to put the Apple Watch’s ECG through large-scale clinical testing Former Insmed CMO Streck resurfaces at Alder On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopes EuroBiotech Report—EMA-Brexit, AstraZeneca, Juvenescence round, Verona fail and Orchard FiercePharmaAsia—Gilead’s clinical VP; Aurobindo buys Spectrum assets; Aslan’s lead drug Chutes & Ladders—Exoduses continue at AstraZeneca Featured Story | | | Friday, January 18, 2019 Celgene is pushing ahead with its immuno-oncology dealmaking program while working toward its $74 billion takeout by Bristol-Myers Squibb. The big biotech ended the week by expanding its CAR-T toolkit via a deal with Obsidian Therapeutics and placing an $80 million bet on Kyn Therapeutics. |
|
|
| This week's sponsor is Sprout BioVentures. | | | Announcing the Golden Sprout Competition
High-potential start-ups are encouraged to apply for the Golden Sprout Award. Winners receive 6 months of chemistry support (2 FTEs) at no cost. Application period closes February 28, 2019. Click here for more information. |
Top Stories Friday, January 18, 2019 Novartis has teamed up with the University of Oxford to use artificial intelligence to improve drug development. The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials to better understand diseases important to Novartis’ prospects. Thursday, January 17, 2019 Apple and Johnson & Johnson are teaming up on a multiyear research study to see if the latest Apple Watch can help catch and diagnose elderly people with atrial fibrillation earlier and faster than before. Friday, January 18, 2019 A few days after leaving Insmed to take up an “employment opportunity on the West Coast,” Paul Streck has popped up at migraine specialist Alder BioPharmaceuticals. Friday, January 18, 2019 Eli Lilly agreed to shell out $8 billion last week for Loxo Oncology in a deal executives billed as a boost for its cancer goals. Good thing, too, given a Friday setback for soft tissue sarcoma drug Lartruvo, which failed a phase 3 trial—so much so that Lilly will stop promoting the drug. Thursday, January 17, 2019 In this week's EuroBiotech Report, EMA raises staff retention forecast, Berman swaps AstraZeneca for Immunocore and Juvenescence raises $46 million. Friday, January 18, 2019 Gilead loses its vice president of clinical research to NASH-focused Terns; Spectrum unloads its marketed portfolio to India's Aurobindo in a deal worth $300 million; Aslan's lead drug varlitinib misses the mark in a gastric cancer trial; and more. Friday, January 18, 2019 CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs. Those moves plus more hirings, firings and retirings throughout the industry. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Sponsored by: DeciBio Consulting With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Presented by: Aprecia Get ahead of looming challenges in the market that include both generic products and new branded drugs. Sponsored by: Oracle Health Sciences New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM). Sponsored by: Veeva Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami 2nd Innovative Regulatory Pathways Summit January 28, 2019, 8 AM - January 29, 2019, 2:45 PM | Sheraton Pentagon City Hotel, Arlington, VA BIO CEO & Investor Conference February 11-12, 2019 | New York Marriott Marquis Asia-Pacific Compliance Training for Life Sciences Professionals March 4-7, 2019 | Singapore 2019 Bridging Clinical Research & Clinical Health Care Collaborative March 4–5, 2019 | National Academy of Sciences | Washington, D.C. BIO Asia International Conference March 5-6, 2019 | Grand Hyatt Tokyo | Tokyo, Japan Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! |
